19 result(s) for "Heart"
-
1.
Ceramides, P Evaluating for the risk of major adverse cardiovascular events within the next 1 to 5 years
MI-Heart Ceramides is a blood test that measures risk for adverse cardiovascular events and quantifies plasma ceramides. Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque.Key Value PROCEDURE_ID 114982 PROCEDURE_NAME CERAMIDES, PLASMA ORDER_DISPLAY_NAME Ceramides, P PROCEDURE_MASTER_NUMBER LAB11313 epic_synonyms pdm 1859767 cpt 0119U LOINC Code: 93883-7 clinical_info Evaluating for the risk of major adverse cardiovascular events within the next 1 to 5 years
MI-Heart Ceramides is a blood test that measures risk for adverse cardiovascular events and quantifies plasma ceramides. Plasma ceramides are predictors of adverse cardiovascular events resulting from unstable atherosclerotic plaque.methodology Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) reference_values MI-Heart Ceramide Risk Score:
0-2 Lower risk
3-6 Moderate risk
7-9 Increased risk
10-12 Higher risk
Ceramide (16:0): 0.19-0.36 mcmol/L
Ceramide (18:0): 0.05-0.14 mcmol/L
Ceramide (24:1): 0.65-1.65 mcmol/L
Ceramide (16:0)/(24:0): <0.11
Ceramide (18:0)/(24:0): <0.05
Ceramide (24:1)/(24:0): <0.45
Reference values have not been established for patients who are <18 years of age.
Note: Ceramide (24:0) alone has not been independently associated with disease and will not be reported.performing_location Mayo Clinic Laboratories compendium_synonyms volume 3 results [{"base_name": "CERAMIDE1624", "common_name": "CERAMINE 16 240", "external_name": "Ceramide (16:)/(24:0) ratio", "component_name": "CERAMIDE (16:)/(24:0)"}, {"base_name": "CERAMIDE24", "common_name": "CERAM24", "external_name": "Ceramide (24:1)", "component_name": "CERAMIDE (24:1)"}, {"base_name": "CERAMIDE160", "common_name": "CERAMIDE 160", "external_name": "Ceramide (16:0)", "component_name": "CERAMIDE (16:0)"}, {"base_name": "CERAMIDE1824", "common_name": "CERAM1824RT", "external_name": "Ceramide (18:0)/(24:0) ratio", "component_name": "CERAMIDE (18:0)/(24:0)"}, {"base_name": "CERAMIDE180", "common_name": "CERAMIDE 180", "external_name": "Ceramide (18:0)", "component_name": "CERAMIDE (18:0)"}, {"base_name": "CERAMIDESCO", "common_name": "CERAMSC", "external_name": "MI-Heart Ceramide Risk Score", "component_name": "CERAMIDE SCORE"}, {"base_name": "CERAMIDE2424", "common_name": "CERAM2424RT", "external_name": "Ceramide (24:1)/(24:0) ratio", "component_name": "CERAMIDE (24:1)/(24:0)"}] name Ceramides, P weight 1800 match_type result component token rank 8 -
2.
N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) An aid in the diagnosis of congestive heart failure.
Key Value PROCEDURE_ID 860 PROCEDURE_NAME B-TYPE NATRIURETIC PEPTIDE ORDER_DISPLAY_NAME N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) PROCEDURE_MASTER_NUMBER LAB106 epic_synonyms NT PROBRAIN NATRIURETIC PEPTIDE B-TYPE NATRIURETIC PEPTIDE BNP pdm 5600161 cpt 83880 clinical_info An aid in the diagnosis of congestive heart failure. methodology Electrochemiluminescence Immunoassay reference_values 0-300 pg/mL
performing_location Northwell Health Laboratories compendium_synonyms ["BNP"] volume 172488 results [{"base_name": "PROBNP", "common_name": "PRO BNP", "external_name": "NT-proBNP", "component_name": "SERUM PRO-BRAIN NATRIURETIC PEPTIDE"}] name N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) weight 600 match_type clinical info substring rank 15 -
3.
Lipoprotein (a) Lp(a) is an independent prospective risk factor for coronary heart disease. Lp(a) determination is intended for use in conjunction with clinical evaluation, patient risk assessment, and other lipid tests to evaluate disorders of lipid metabolism and to assess coronary heart disease in specific populations.
Key Value PROCEDURE_ID 64461 PROCEDURE_NAME LIPOPROTEIN A (LPA) ORDER_DISPLAY_NAME Lipoprotein (a) PROCEDURE_MASTER_NUMBER LAB563 epic_synonyms LPA LIPOPROTEIN A, SERUM LP(A) LP(A) APOPROTEIN pdm 5904270 cpt 83695 clinical_info Lp(a) is an independent prospective risk factor for coronary heart disease. Lp(a) determination is intended for use in conjunction with clinical evaluation, patient risk assessment, and other lipid tests to evaluate disorders of lipid metabolism and to assess coronary heart disease in specific populations. methodology Immunoturbidimetric reference_values <75 nmol/L; values ≥75 nmol/L may indicate independent risk factor for CHD. performing_location LabCorp compendium_synonyms volume 21363 results [{"base_name": "LIPOA", "common_name": "LIPOPROTEIN A", "external_name": "Lipoprotein (a)", "component_name": "LIPOPROTEIN (A)"}] name Lipoprotein (a) weight 600 match_type clinical info substring rank 15 -
4.
Methylmalonic Acid (MMA) and Homocysteine Screen patients who may be at risk for heart disease and stroke To diagnose and monitor vitamin B12 (cobalamin) deficiency.
Key Value PROCEDURE_ID 64593 PROCEDURE_NAME METHYLMALONIC ACID (MMA) AND HOMOCYSTEINE ORDER_DISPLAY_NAME Methylmalonic Acid (MMA) and Homocysteine PROCEDURE_MASTER_NUMBER LAB694 epic_synonyms METHHOMO pdm 5909830 cpt 83090 83921 clinical_info Screen patients who may be at risk for heart disease and stroke To diagnose and monitor vitamin B12 (cobalamin) deficiency. methodology Liquid chromatography/tandem mass spectrometry (LC/MS-MS)- Methylmalonic Acid Enzymatic- Homocysteine reference_values
Methylmalonic Acid: 0 - 378 nmol/LHomocysteine
Age
Male (µmol/L)
Female (µmol/L)
0 to 6 m
0.0–11.5
0.0–11.5
7 m to 1 y
0.0–10.0
0.0–10.0
2 to 12 y
0.0–9.0
0.0–9.0
13 to 17 y
0.0–11.0
0.0–11.0
18 to 60 y
0.0–14.5
0.0–14.5
61 to 70 y
0.0–17.2
0.0–17.2
71 to 80 y
0.0–19.2
0.0–19.2
>80 y
0.0–21.3
0.0–21.3
performing_location LabCorp compendium_synonyms volume 4593 results [{"base_name": "METHYLLVL", "common_name": "METHYLMALONIC ACID S", "external_name": "Methylmalonic Acid Level, Serum", "component_name": "METHYLMALONIC ACID LEVEL, SERUM"}, {"base_name": "HOMOCYSTEINE", "common_name": "HOMOCYSTEINE LEVEL", "external_name": "Homocysteine Level", "component_name": "HOMOCYSTEINE LEVEL"}] name Methylmalonic Acid (MMA) and Homocysteine weight 600 match_type clinical info substring rank 15 -
5.
Lipoprotein Associated Phospholipase A2 Activity The PLAC® test for Lp-PLA2 Activity is an enzyme assay for the in vitro quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) activity in EDTA plasma and serum. Lp-PLA2 activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) ...
Key Value PROCEDURE_ID 56200 PROCEDURE_NAME LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 ORDER_DISPLAY_NAME Lipoprotein Associated Phospholipase A2 Activity PROCEDURE_MASTER_NUMBER LAB1045 epic_synonyms PLA2 LPPLA2 PLAC LPPLA LP-PLA2 ACTIVITY, S pdm 5910180 cpt 83698 clinical_info The PLAC® test for Lp-PLA2 Activity is an enzyme assay for the in vitro quantitative determination of Lp-PLA2 (lipoprotein-associated phospholipase A2) activity in EDTA plasma and serum. Lp-PLA2 activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events methodology Spectrophotometric, enzymatic assay reference_values • Reduced Risk: <225 nmol/min/mL
• Increased Risk: ≥225 nmol/min/mLperforming_location LabCorp Burlington compendium_synonyms volume 96 results [{"base_name": "LPPLA2", "common_name": "LP PLA2", "external_name": "Lp-PLA2 Activity", "component_name": "LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 ACTIVITY, SERUM"}] name Lipoprotein Associated Phospholipase A2 Activity weight 600 match_type clinical info substring rank 15 -
6.
B-Type Natriuretic Peptide(BNP) ab Support a diagnosis of congestive heart failure (CHF) B-type natriuretic peptide (BNP), also referred to as brain natriuretic peptide, is a member of a family of structurally similar peptide hormones that includes atrial natriuretic peptide.1 BNP is a 32-amino-acid peptide that contains a 17-amino-acid ring structure that is formed as the ...
Key Value PROCEDURE_ID 183364 PROCEDURE_NAME B-TYPE NATRIURETIC PEPTIDE(BNP) AB ORDER_DISPLAY_NAME B-Type Natriuretic Peptide(BNP) ab PROCEDURE_MASTER_NUMBER LAB14064 epic_synonyms B-Type Natriuretic Peptide(BNP)ab BNP pdm 235312 cpt 83880 LOINC Code: 30934-4 clinical_info Support a diagnosis of congestive heart failure (CHF) B-type natriuretic peptide (BNP), also referred to as brain natriuretic peptide, is a member of a family of structurally similar peptide hormones that includes atrial natriuretic peptide.1 BNP is a 32-amino-acid peptide that contains a 17-amino-acid ring structure that is formed as the result of an internal disulfide bond. BNP is predominantly secreted by the ventricles of the heart in response to increased pressure. BNP acts as a vasodilator and has diuretic and natriuretic properties. BNP suppresses both sympathetic tone and the renin-angiotensin system. These physiologic effects serve to reduce intraventricular pressure and improve the symptoms of congestive heart failure (CHF). BNP levels increase with age and can be transiently increased by vigorous exercise.1,2 BNP levels correlate with end-diastolic pressure and tend to be increased in patients with diminished left ventricular ejection fraction.1,3 BNP levels have been shown to be useful in the diagnosis of patients with symptoms that are consistent with CHF. Maisel and coworkers4 found that a BNP cutoff of 75 pg/mL could be used to predict systolic and/or diastolic abnormalities accurately in symptomatic patients referred to echocardiology for left ventricular function studies. They found that this cutoff identified patients with abnormal function from a population of 200 patients with a sensitivity of 95.9%, specificity of 86%, positive predictive value of 98%, and a negative predictive value of 89%. The overall accuracy of the diagnosis with a cutoff of 75 pg/mL was 93%. These results were similar to those found by Dao and coworkers.5 They found that BNP levels could be used to accurately identify patients with CHF from a population of patients presenting at the emergency room with shortness of breath (dyspnea). They found that a BNP value >80 pg/mL could be used to identify patients with CHF from this population with a sensitivity of 97%, specificity of 98%, positive predictive value of 92%, and a negative predictive value of 98%.6 Footnotes 1. Maisel A. B-type natriuretic peptide levels: A potential novel “white count” for congestive heart failure. J Card Fail. 2001; 7(2):183-193. PubMed 11420771 2. McNairy M, Gardetto N, Clopton P, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: Implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J. 2002; 143(3):406-411. PubMed 11868044 3. Valli N, Georges A, Corcuff JB, et al. Assessment of brain natriuretic peptide in patients with suspected heart failure: Comparison with radionuclide ventriculography data. Clin Chim Acta. 2001; 306(1-2):19-26. PubMed 11282090 4. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141(3):367-374. PubMed 11231433 5. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol. 2001; 37(2):379-385. PubMed 11216950 6. Wu AH, Packer M, Smith A et al. Analytical and clinical evaluation of the Bayer ADVIA Centaur Automated B-type natriuretic peptide assay in patients with heart failure: A multisite study. Clin Chem. 2004 May; 50(5):867-873. methodology Immunochemiluminometric assay (ICMA) reference_values 0−100 pg/mL
performing_location LabCorp compendium_synonyms volume 77 results [{"base_name": "BNP", "common_name": "BNP", "external_name": "BNP", "component_name": "BNP"}] name B-Type Natriuretic Peptide(BNP) ab weight 600 match_type clinical info substring rank 15 -
7.
Myocardial Antibody Screen with Reflex to Titer Detection of myocardial Antibodies suggests that a patient's heart disease may have an immunologic component. Myocardial Antibodies are found in the serum of patients with various cardiomyopathies, especially idiopathic dilated cardiomyopahty, myocarditis, rheumatic fever, and Dressler's Syndrome.
Key Value PROCEDURE_ID 114762 PROCEDURE_NAME MYOCARDIAL ANTIBODIES ORDER_DISPLAY_NAME Myocardial Antibody Screen with Reflex to Titer PROCEDURE_MASTER_NUMBER LAB11193 epic_synonyms AMYO MYOCARDIAL ANTIBODIES pdm 5901740 cpt 86255 clinical_info Detection of myocardial Antibodies suggests that a patient's heart disease may have an immunologic component. Myocardial Antibodies are found in the serum of patients with various cardiomyopathies, especially idiopathic dilated cardiomyopahty, myocarditis, rheumatic fever, and Dressler's Syndrome. methodology Immunofluorescence Assay (IFA) reference_values Screen: Negative
Titer: <1:40
If Myocardial Antibody Screen is positive, Myocardial Antibody Titer will be performed at an additional chargeperforming_location Quest Diagnostics' Nichols Institute, Inc. - Chantilly compendium_synonyms volume 27 results [{"base_name": "MYOCAB", "common_name": "MYOCARDIAL ANTIBODIES", "external_name": "Myocardial Antibodies", "component_name": "MYOCARDIAL ANTIBODIES"}] name Myocardial Antibody Screen with Reflex to Titer weight 600 match_type clinical info substring rank 15 -
8.
Galectin-3, Serum Aiding in the prognosis for patients diagnosed with heart failure
Risk-stratification of heart failure patients
An early indication of treatment failure and as a therapeutic target
Heart failure is a complex cardiovascular disorder with a variety of etiologies and heterogeneity with respect to the clinical presen...Key Value PROCEDURE_ID 111602 PROCEDURE_NAME GALECTIN-3, SERUM ORDER_DISPLAY_NAME Galectin-3, Serum PROCEDURE_MASTER_NUMBER LAB10549 epic_synonyms pdm 145902025 cpt 82777-Galectin-3 clinical_info Aiding in the prognosis for patients diagnosed with heart failure
Risk-stratification of heart failure patients
An early indication of treatment failure and as a therapeutic target
Heart failure is a complex cardiovascular disorder with a variety of etiologies and heterogeneity with respect to the clinical presentation of the patient.methodology Enzyme-Linked Immunosorbent Assay (ELISA) reference_values <24 months: not established
2-17 years: < or = 25.0 ng/mL
> or = 18 years: < or = 22.1 ng/mLperforming_location Mayo Clinic Laboratories in Rochester compendium_synonyms volume 11 results [{"base_name": "GALACTIN", "common_name": "GALECTIN 3, SERUM", "external_name": "Galectin-3, Serum", "component_name": "GALECTIN-3, SERUM"}] name Galectin-3, Serum weight 600 match_type clinical info substring rank 15 -
9.
Brugada Syndrome (BrS) Panel Confirmation of a clinical diagnosis in symptomatic patients Risk assessment of asymptomatic family members of a proband with Brugada syndrome Recurrence risk calculation Differentiation of hereditary BrS from other acquired or genetic heart conditions Prenatal diagnosis in families with a known mutation
Key Value PROCEDURE_ID 115545 PROCEDURE_NAME BRUGADA SYNDROME (BRS) PANEL ORDER_DISPLAY_NAME Brugada Syndrome (BrS) Panel PROCEDURE_MASTER_NUMBER LAB11615 epic_synonyms pdm 1659869 cpt \81406 81404 81407 clinical_info Confirmation of a clinical diagnosis in symptomatic patients Risk assessment of asymptomatic family members of a proband with Brugada syndrome Recurrence risk calculation Differentiation of hereditary BrS from other acquired or genetic heart conditions Prenatal diagnosis in families with a known mutation methodology Deletion/Duplication Analysis Next-Gen Sequencing Genes: ABCC9, CACNA1C, CACNA2D1, CACNB2, GPD1L, HCN4, KCND3, KCNE3, KCNH2, KCNJ8, PKP2, SCN10A, SCN1B, SCN2B, SCN3B, SCN5A, TRPM4 reference_values performing_location GeneDx compendium_synonyms volume 4 results [{"base_name": "BRUGADA", "common_name": "BRUGADA SYNDROME BRS PANEL", "external_name": "Brugada Syndrome (BrS) Panel", "component_name": "BRUGADA SYNDROME (BRS) PANEL"}] name Brugada Syndrome (BrS) Panel weight 600 match_type clinical info substring rank 15 -
10.
Allomap (CareDx) Requires coordination with CareDx and communication with the local laboratory prior to collection. AlloMap Molecular Expression Testing (the AlloMap Test) is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononucl...
Key Value PROCEDURE_ID 182862 PROCEDURE_NAME ALLOMAP (CAREDX) ORDER_DISPLAY_NAME Allomap (CareDx) PROCEDURE_MASTER_NUMBER LAB13966 epic_synonyms ALLOMAP pdm 235106 cpt clinical_info Requires coordination with CareDx and communication with the local laboratory prior to collection. AlloMap Molecular Expression Testing (the AlloMap Test) is an In Vitro Diagnostic Multivariate Index Assay (IVDMIA) test service, performed in a single laboratory, assessing the gene expression profile of RNA isolated from peripheral blood mononuclear cells (PBMC). AlloMap Testing is intended to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection (ACR) at the time of testing in conjunction with standard clinical assessment. The AlloMap Test is indicated for heart transplant recipients: • 15 years of age or older • At least 2 months (≥ 55 days) post-transplant methodology AlloMap Molecular Expression - In Vitro Diagnostic Multivariate Index Assay reference_values performing_location Natera Inc. 201 Industrial Rd Ste 410, San Carlos, CA 94070 compendium_synonyms volume 2 results [{"base_name": "ALLOMAP", "common_name": "ALLOMAP", "external_name": "Allomap", "component_name": "ALLOMAP"}] name Allomap (CareDx) weight 600 match_type clinical info substring rank 15 -
11.
Allosure (CareDx) Requires coordination with CareDx. AlloSure-Heart measures a biomarker in your blood called donor-derived cell-free DNA (dd-cfDNA). When dd-cfDNA increases, it provides an early warning sign that there could be an issue with the heart.
Key Value PROCEDURE_ID 184576 PROCEDURE_NAME ALLOSURE (CAREDX) ORDER_DISPLAY_NAME Allosure (CareDx) PROCEDURE_MASTER_NUMBER LAB14268 epic_synonyms pdm 235273 cpt clinical_info Requires coordination with CareDx. AlloSure-Heart measures a biomarker in your blood called donor-derived cell-free DNA (dd-cfDNA). When dd-cfDNA increases, it provides an early warning sign that there could be an issue with the heart. methodology reference_values performing_location Natera, Inc. 201 Industrial Rd, Ste 410. San Carlo, CA 94070 compendium_synonyms volume results [{"base_name": "ALLOSURE", "common_name": "ALLOSURE", "external_name": "Allosure", "component_name": "ALLOSURE"}] name Allosure (CareDx) weight 600 match_type clinical info substring rank 15 -
12.
Hemochromatosis (HFE) Mutation Molecular Detection Hereditary Hemochromatosis (HH) is one of the most common genetic disorders, found most often in people of Northern European descent. It is a disorder of iron metabolism, characterized by inappropriately high absorption of iron by the gastrointestinal mucosa. Clinical HH is characterized by excessive storage of iron in several organs of the body...
Key Value PROCEDURE_ID 64733 PROCEDURE_NAME HEMOCHROMATOSIS MUTATION ORDER_DISPLAY_NAME Hemochromatosis (HFE) Mutation Molecular Detection PROCEDURE_MASTER_NUMBER LAB833 epic_synonyms HFE GENE, HEREDITARY HEMOCHROMATOSIS, IORN OVERLOAD, C282Y AND H63D C282Y HFE GENE HEREDITARY HEMOCHROMATOSIS H63D pdm 5160990 cpt 81256 clinical_info Hereditary Hemochromatosis (HH) is one of the most common genetic disorders, found most often in people of Northern European descent. It is a disorder of iron metabolism, characterized by inappropriately high absorption of iron by the gastrointestinal mucosa. Clinical HH is characterized by excessive storage of iron in several organs of the body including the liver, pancreas, endocrine glands, heart, skin, joints, testes, and intestinal lining. The buildup of iron in these organs can lead to hepatomegaly, hepatic cirrhosis, hepatocellular carcinoma, diabetes mellitus, cardiomyopathy, hypogonadism, arthritis (especially involving the metacarpophalangeal joints) and progressive increase in skin pigmentation. The prevalence of HH varies from 1 per 200-400 individuals in Caucasian population, to 1 per 220-250 in populations of Nordic or Celtic ancestry. The pattern of inheritance is recessive autosomal. methodology Real Time PCR Samples are analyzed for the hereditary hemochromatosis (HH) mutation C282Y, and H63D in the HFE gene. reference_values An interpretive report will be provided.
performing_location Northwell Health Laboratories compendium_synonyms volume results [{"base_name": null, "common_name": null, "external_name": null, "component_name": null}] name Hemochromatosis (HFE) Mutation Molecular Detection weight 600 match_type clinical info substring rank 15 -
13.
Lipid Panel This panel contains Cholesterol LDL Cholesterol (calculated) High-Density Lipoprotein (HDL), Cholesterol Calculated Non-HDL Cholesterol Triglycerides
Key Value PROCEDURE_ID 684 PROCEDURE_NAME LIPID PANEL ORDER_DISPLAY_NAME Lipid Panel PROCEDURE_MASTER_NUMBER LAB18 epic_synonyms LDL CHOLESTEROL LIPID PROFILE CORONARY RISK PANEL HDL pdm 5300102 cpt 82465 - cholesterol 83718 - lipoprotein, direct measurement; high density cholesterol (HDL cholesterol) 84478 - triglycerides clinical_info This panel contains Cholesterol LDL Cholesterol (calculated) High-Density Lipoprotein (HDL), Cholesterol Calculated Non-HDL Cholesterol Triglycerides methodology reference_values Cholesterol
Optimal Cholesterol concentration: <200 mg/dL (for adults) ; <170 mg/dL (for children)Triglycerides
Optimal Triglycerides concentration: <150 mg/dL (for adults) ; < 90 mg/dL (for children)
Triglyceride concentration can be influenced when measured in the non-fasting stateHDL Cholesterol
HDL cholesterol less than 40 mg/dL is a risk factor for cardiovascular diseaseLDL cholesterol
Optimal LDL cholesterol concentration vary based on ASCVD risk and treatment goals.
All Patients: < 100 mg/dL
Patients at High Risk ASCVD: < 70 mg/dL
Patients at Very High Risk ASCVD: < 55 mg/dL
Consider Familial Hypercholesterolemia when LDL > 190 mg/dL.Non-HDL Cholesterol
Optimal Non-HDL Cholesterol (Non-HDL-C) vary based on ASCVD risk and treatment goals.
All Patients: < 130 mg/dL
Patients at High Risk ASCVD: < 100 mg/dL
Patients at Very High Risk ASCVD: < 85 mg/dL
Consider Familial Hypercholesterolemia when Non-HDL > 220 mg/dL.The suggested cutoff points are based on recommendations from the American College of Cardiology/American Heart Association
(ACC/AHA) guidelines on the management of blood cholesterol [Circulation. 2019;139:e1082–e1143], and 2022 ACC Expert
Consensus Decision Pathway [(J Am Coll Cardiol. 2022 Oct, 80 (14) 1366–1418]performing_location Northwell Health Laboratories compendium_synonyms volume 1118712 results [{"base_name": "CHOL", "common_name": "CHOLESTEROL", "external_name": "Cholesterol", "component_name": "CHOLESTEROL, SERUM"}, {"base_name": "LDL", "common_name": "NON HDL CHOL LDL VLDL", "external_name": "Non-HDL Cholesterol", "component_name": "NON-HDL CHOLESTEROL"}, {"base_name": "TRIG", "common_name": "TRIGLYCERIDES", "external_name": "Triglycerides", "component_name": "TRIGLYCERIDES, SERUM"}, {"base_name": "HDL", "common_name": "HDL", "external_name": "HDL Cholesterol", "component_name": "HDL CHOLESTEROL, SERUM"}, {"base_name": "LDLCALC", "common_name": "LDL CALC", "external_name": "LDL Cholesterol (Calc)", "component_name": "LDL CALCULATED"}] name Lipid Panel weight 400 match_type reference values substring rank 17 -
14.
Troponin T, High Sensitivity Preferred biomarker to aid in the diagnosis of myocardial injury and acute myocardial infarction.
Key Value PROCEDURE_ID 926 PROCEDURE_NAME TROPONIN T ORDER_DISPLAY_NAME Troponin T, High Sensitivity PROCEDURE_MASTER_NUMBER LAB139 epic_synonyms TROPTHS HS-TNT CARDIAC TNT TNT pdm 1853066 cpt 84484 clinical_info Preferred biomarker to aid in the diagnosis of myocardial injury and acute myocardial infarction. methodology Electrochemiluminescent Immunoassay (ECLIA) reference_values Troponin results should be interpreted in conjunction with the patient’s current clinical presentation, symptoms, medical history, and ECG findings. A single troponin result is not definitive in diagnosing acute myocardial infarction due to the release kinetics of cardiac troponin. Serial measurements are necessary for ruling in or ruling out suspected non-ST-segment elevation myocardial infarction (NSTEMI). Chronic renal impairment can lead to persistently elevated troponin levels. Elevated troponin concentration can also be seen in patients with, acute heart failure, myocarditis, rhabdomyolysis, or polymyositis. Hemolysis may cause falsely low troponin T results
performing_location Northwell Health Laboratories - Rapid Response Laboratories compendium_synonyms [""] volume 210686 results [{"base_name": "TROPONINTHS", "common_name": "TROPONIN T HS", "external_name": "Troponin T, High Sensitivity", "component_name": "TROPONIN T, HIGH SENSITIVITY"}, {"base_name": "TROPSAM", "common_name": "TROPONIN SAMPLING TIME", "external_name": "Troponin Sampling Time", "component_name": "TROPONIN SAMPLING TIME"}] name Troponin T, High Sensitivity weight 400 match_type reference values substring rank 17 -
15.
LDL Cholesterol, Direct
Key Value PROCEDURE_ID 852 PROCEDURE_NAME LDL CHOLESTEROL, DIRECT ORDER_DISPLAY_NAME LDL Cholesterol, Direct PROCEDURE_MASTER_NUMBER LAB102 epic_synonyms LDC LOW DENSITY LIPOPROTEIN pdm 5300086 cpt 83721 LOINC Code: 18262-6 clinical_info methodology Homogeneous Enzymatic Colorimetric reference_values All Patients: < 100 mg/dL
High Risk ASCVD: < 70 mg/dL
Very High Risk ASCVD: < 55 mg/dLASCVD = atherosclerotic cardiovascular disease
The suggested cutoff points are based on recommendations from the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the management of blood cholesterol [Circulation. 2019;139:e1082-e1143].
performing_location Northwell Health Laboratories compendium_synonyms volume 32289 results [{"base_name": "LDLDIRECT", "common_name": "LDL DIRECT", "external_name": "LDL Cholesterol, Direct", "component_name": "LDL CHOLESTEROL, DIRECT"}] name LDL Cholesterol, Direct weight 400 match_type reference values substring rank 17 -
16.
Omega-3 and 6 Fatty Acids OmegaCheck® may be performed on individuals with hypercholesterolemia, hypertriglyceridemia, hypertension, and/or those high metabolic or cardiovascular risk.
Key Value PROCEDURE_ID 115215 PROCEDURE_NAME OMEGA-3 AND 6 FATTY ACIDS ORDER_DISPLAY_NAME Omega-3 and 6 Fatty Acids PROCEDURE_MASTER_NUMBER LAB11439 epic_synonyms OmegaCheck Omega 3 Omega Check Omega-3 and 6 Fatty Acids pdm 1759536 cpt 82542 clinical_info OmegaCheck® may be performed on individuals with hypercholesterolemia, hypertriglyceridemia, hypertension, and/or those high metabolic or cardiovascular risk. methodology Chromatography/Mass Spectrometry This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes. reference_values See Report
Performing Laboratory
Cleveland HeartLab, Inc
6701 Carnegie Avenue, Suite 500
Cleveland, OH 44103-462performing_location Quest Diagnostics' Nichols Institute, Inc. - Chantilly compendium_synonyms ["Omega Check"] volume 641 results [{"base_name": "EPA", "common_name": "EICOSAPENTAENOIC ACID", "external_name": "EPA", "component_name": "EICOSAPENTAENOIC ACID"}, {"base_name": "DPA", "common_name": "DPA", "external_name": "DPA", "component_name": "DPA"}, {"base_name": "LINOLACD", "common_name": "LINOLEIC ACID", "external_name": "Linoleic Acid", "component_name": "LINOLEIC ACID"}, {"base_name": "OMEG63RAT", "common_name": "OMEGA 6 OMEGA 3 RATIO", "external_name": "Omega-6/Omega-3 Ratio", "component_name": "OMEGA-6/OMEGA-3 RATIO"}, {"base_name": "ARACHEPA", "common_name": "ARACHIDONIC ACID EPA RATIO", "external_name": "Arachidonic Acid/EPA Ratio", "component_name": "ARACHIDONIC ACID/EPA RATIO"}, {"base_name": "ARACHACID", "common_name": "ARACHIDONIC ACID", "external_name": "Arachidonic Acid", "component_name": "ARACHIDONIC ACID"}, {"base_name": "DHA", "common_name": "DOCOSAHEXAENOIC ACID", "external_name": "DHA", "component_name": "DOCOSAHEXAENOIC ACID"}, {"base_name": "OMEGACHECK", "common_name": "OMEGACHECK TM", "external_name": "Omegacheck (Tm)", "component_name": "OMEGACHECK (TM)"}, {"base_name": "OMEGA3", "common_name": "OMEGA 3 TOTAL", "external_name": "Omega-3 Total", "component_name": "OMEGA-3 TOTAL"}, {"base_name": "OMEGA6", "common_name": "OMEGA 6 TOTAL", "external_name": "Omega-6 Total", "component_name": "OMEGA-6 TOTAL"}] name Omega-3 and 6 Fatty Acids weight 400 match_type reference values substring rank 17 -
17.
TMAO (Trimethylamine N-Oxide) TMAO (trimethylamine N-oxide) which has been shown to regulate various physiological processes involved in the development of atherosclerosis.
Key Value PROCEDURE_ID 135251 PROCEDURE_NAME TMAO (TRIMETHYLAMINE N-OXIDE ORDER_DISPLAY_NAME TMAO (Trimethylamine N-Oxide) PROCEDURE_MASTER_NUMBER LAB12029 epic_synonyms TMAO TMAO (Trimethylamine N-Oxide) pdm 235045 cpt 82542 LOINC Code: 90360-9 clinical_info TMAO (trimethylamine N-oxide) which has been shown to regulate various physiological processes involved in the development of atherosclerosis. methodology Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) reference_values < 6.2 uM
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Cardiometabolic Center of Excellence at Cleveland HeartLab. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
performing_location Quest Diagnostics Nichols Institute to Cleveland Heart Lab compendium_synonyms volume 70 results [{"base_name": "TMAO", "common_name": "TMAO", "external_name": "TMAO (Trimethylamine N-oxide)", "component_name": "TMAO (TRIMETHYLAMINE N-OXIDE)"}] name TMAO (Trimethylamine N-Oxide) weight 700 match_type reference values substring rank 17 -
18.
Oxidized LDL The oxidized LDL test may be ordered for individuals at low or intermediate risk of metabolic syndrome or cardiovascular disease. In addition, this test is useful in individuals who have cardiovascular disease and are at risk for an adverse cardiac event.
Key Value PROCEDURE_ID 189659 PROCEDURE_NAME OXIDIZED LDL ORDER_DISPLAY_NAME Oxidized LDL PROCEDURE_MASTER_NUMBER LAB4130 epic_synonyms OXLDL pdm 245459 cpt 83520 LOINC Code: 54238-1 clinical_info The oxidized LDL test may be ordered for individuals at low or intermediate risk of metabolic syndrome or cardiovascular disease. In addition, this test is useful in individuals who have cardiovascular disease and are at risk for an adverse cardiac event. methodology Enzyme Linked Immunosorbent Assay (ELISA) reference_values < 60 U/L
Performing Laboratory
Cleveland HeartLab Inc
6701 Carnegie Avenue Suite 500
Cleveland, OH 44103performing_location Quest Diagnostics compendium_synonyms volume 9 results [{"base_name": "OXIDIZEDLDL", "common_name": "OXIDIZED LDL", "external_name": "Oxidized LDL", "component_name": "OXIDIZED LDL"}] name Oxidized LDL weight 400 match_type reference values substring rank 17 -
19.
ADMA (Asymmetric dimethylarginine) and SDMA (Symmetric dimethylarginine) ADMA and SDMA may be measured in individuals with multiple risk factors for the development of cardiovascular disease.
Key Value PROCEDURE_ID 114850 PROCEDURE_NAME ASYMMETRIC AND SYMMETRIC DIMETHYLARGININE ORDER_DISPLAY_NAME ADMA (Asymmetric dimethylarginine) and SDMA (Symmetric dimethylarginine) PROCEDURE_MASTER_NUMBER LAB11238 epic_synonyms ADMA/SDMA pdm 235267 cpt 82542 clinical_info ADMA and SDMA may be measured in individuals with multiple risk factors for the development of cardiovascular disease. methodology Liquid Chromatography/Tandem Mass Spectrometry (LC/MS/MS) reference_values ADMA (Asymmetric dimethylarginine) <100 ng/mL
SDMA (Symmetric dimethylarginine) 73-135 ng/mL
performing_location Quest Diagnostics Chantilly Test performed by Cleveland HeartLab, Inc 6701 Carnegie Avenue, Suite 500 Cleveland, OH 44103-4623 compendium_synonyms volume 14 results [{"base_name": "SDMA", "common_name": "SDMA SYMMETRIC DIMETHYLARGININE", "external_name": "SDMA (Symmetric dimethylarginine)", "component_name": "SDMA (SYMMETRIC DIMETHYLARGININE)"}, {"base_name": "ADMA", "common_name": "ADMA ASYMMETRIC DIMETHYLARGININE", "external_name": "ADMA (Asymmetric dimethylarginine)", "component_name": "ADMA (ASYMMETRIC DIMETHYLARGININE)"}] name ADMA (Asymmetric dimethylarginine) and SDMA (Symmetric dimethylarginine) weight 300 match_type performing location substring rank 18